High Risk of ESRD in Type 1 Diabetes: New Strategies Are Needed to Retard Progressive Renal Function Decline

Seminars in Nephrology

Volumn 32, Issue 5, 2012, Pages 407-414

  Krolewski, Andrzej S ^a   Bonventre, Joseph V ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; CYSTATIN C; GLUCOSE; HEMOGLOBIN A1C; RENIN; RENIN INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MODEL; DRUG TARGETING; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; PANCREAS TRANSPLANTATION; PATIENT CARE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; STEM CELL TRANSPLANTATION;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84867375222     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.07.002     Document Type: Article

References (51)

1. Nawroth P.P., Isermann B. Mechanisms of diabetic nephropathy-old buddies and newcomers part 1. Exp Clin Endocrinol Diabetes 2010, 118:571-576.
2. Nawroth P.P., Isermann B. Mechanisms of diabetic nephropathy-old buddies and newcomers part 2. Exp Clin Endocrinol Diabetes 2010, 118:667-672.
3. Thomas M.C. Pathogenesis and progression of proteinuria. Contrib Nephrol 2011, 170:48-56.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
5. de Boer I.H., Sun W., Cleary P.A., et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011, 365:2366-2376.
6. Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl 1):S13-S61. American Diabetes Association.
7. Saaddine J.B., Cadwell B., Gregg E.W., Engelgau M.M., Vinicor F., Imperatore G., et al. Improvements in diabets processes of care and intermediaye outcomes: United States, 1988-2002. Ann Inter Med 2006, 144:465-474.
8. Paris C.A., Imperatore G., Klingensmith G., Petitti D., Rodriguez B., Anderrason A.M., et al. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for diabetes in youth study. J Pediatr 2009, 155:183-189.
9. Krolewski A.S., Laffel L.M., Krolewski M., Quinn M., Warram J.H. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995, 332:1251-1255.
10. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of DN. BMJ 1982, 285:685-688.
11. Parving H.H., Andersen A.R., Smidt U.M., Svendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in DN. Lancet 1982, 1:1175-1179.
12. Trocha A.K., Schmidtke C., Didjurgeit U., Muhlhauser I., Bender R., Berger M., et al. Effect of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study. J Hypertens 1999, 17:1497-1503.
13. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Study Group.
14. Carter B.L. Implementing the new guidelines for hypertension: JNC 7, ADA, WHO-ISH. J Manag Care Pharm 2004, 10(Suppl A):S18-S25.
15. Zatz R., Meyer T.W., Rennke H.G., Brenner B.M. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985, 82:5963-5967.
16. Hollenberg N.K., Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993, 153:2426-2435.
17. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
18. Mauer M., Zinman B., Gardiner R., Suissa S., Sinaiko A., Strand T., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
19. Viberti G., Mogensen C.E., Groop L.C., Pauls J.F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 272:275-279.
20. Laffel L.M., McGill J.B., Gans D.J. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497-504.
21. Parving H.H., Mauer M., Ritz E. Diabetic nephropathy. Brenner and Rector's the kidney 2004, 1777-1818. Elsevier, Inc, Philadelphia. 7th ed. B.M. Brenner (Ed.).
22. Perkins B.A., Ficociello L.H., Roshan B., Warram J.H., Krolewski A.S. In patients with type 1 diabetes and new onset micro-albuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57-64.
23. Macisaac R.J., Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertension 2011, 20:246-257.
24. Rosolowsky E.T., Skupien J., Smiles A.M., Niewczas M.A., Roshan B., Stanton R., et al. Risk of ESRD in type 1 diabetes remains high in spite of renoprotection. J Am Soc Nephrol 2011, 22:545-553.
25. Forsblom C., Harjutsalo V., Thorn L., Wadén J., Tolonen N., Saraheimo M., et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011, 22:537-544.
26. Perkins B.A., Ficociello L.H., Silva K.H., Finkelstein D.M., Warram J.H., Krolewski A.S. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
27. Perkins B.A., Ficociello L.H., Ostrander B.E., Silva K.H., Weinberg J., Warram J.H., et al. Microalbuminuria and risk of early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007, 18:1353-1361.
28. Merchant M.L., Perkins B.A., Boratyn G.M., Ficociello L.H., Wilkey D.W., Barati M.T., et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009, 20:2065-2074.
29. Skupien J., Warram J.H., Smiles A.M., Niewczas M.A., Gohda T., Pezzolesi M.G., et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 2012 May 23, [Epub ahead of print].
30. Krolewski M., Eggers P.W., Warram J.H. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996, 50:2041-2046.
31. Zahran A., El Husseini A., Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate?. A literature review. Am J Nephrol 2007, 27:197-205.
32. Eriksen B.O., Mathisen U.D., Melsom T., Ingebretsen O.C., Jenssen T.G., Njølstad I., et al. Cystatin C is not a better estimator of GFR than plasma creatinine in the general population. Kidney Int 2010, 78:1305-1311.
33. Krolewski A.S., Warram J.H., Forsblom C., Smiles A.M., Thorn L., Skupien J., et al. Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes. Diabetes Care 2012 Jul 30, [Epub ahead of print].
34. Gohda T., Niewczas M.A., Ficociello L.H., Walker W.H., Skupien J., Rosetti F., et al. Circulating TNF receptors 1 and 2 predict stage 3 of CKD in type 1 diabetes. J Am Soc Nephrol 2012, 23:516-524.
35. Niewczas M.A., Gohda T., Skupien J., Smiles A.M., Walker W.H., Rosetti F., et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012, 23:507-515.
36. Thomas M.C., Groop P.H. New approaches to the treatment of nephropathy in diabetes. Expert Opin Investig Drugs 2011, 20:1057-1071.
37. Stanton R.C. Oxidative stress and diabetic kidney disease. Curr Diab Rep 2011, 11:330-336.
38. Ruggenenti P., Cravedi P., Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010, 6:319-330.
39. Mathew A., Cunard R., Sharma K. Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol 2011, 170:217-227.
40. Goel G., Perkins B.A. Can improved glycemic control slow renal function decline at all stages of diabetic nephropathy?. Semin Nephrol 2012, 32:423-431.
41. Doria A., Niewczas M.A., Fiorina P. Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?. Semin Nephrol 2012, 32:437-444.
42. Bonventre J.V. Can we target tubular damage to prevent renal function decline in diabetes?. Semin Nephrol 2012, 32:452-462.
43. Humphreys B.D. Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy. Semin Nephrol 2012, 32:463-470.
44. Mima A., Qi W., King G.L. Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin Nephrol 2012, 32:471-478.
45. Osafune K. iPS cell technology-based research for the treatment of diabetic nephropathy. Semin Nephrol 2012, 32:479-485.
46. Gilbert R.E., Zhang Y., Yuen D.A. Cell therapy for diabetic nephropathy: is the future, now?. Semin Nephrol 2012, 32:486-493.
47. Chokrungvaranon N., Deer J., Reaven P.D. Intensive glycemic control and cardiovascular disease; are there patients who may benefit?. Postgrad Med 2011, 123:114-123.
48. Degome E.M., Rivera G., Lilly S.M., Usman M.H., Mohler E.R. Personalized vascular medicine; individualizing drug therapy. Vasc Med 2011, 16:391-404.
49. Higgins M.J., Baselga J. Targeted therapies for brest cancer. J Clin Invest 2011, 121:3797-3803.
50. Cantarovich D., Perrone V. Pancreas transplant as treatment to arrest renal function decline in patients with type 1 diabetes and proteinuria. Semin Nephrol 2012, 32:432-436.
51. Pavlakis M., Kher A. Pre-emptive kidney transplantation to improve survival in patients with type 1 diabetes and imminent risk of ESRD. Semin Nephrol 2012, 32:505-511.